Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 10/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.38 |
| ▸ | PAK4 | O96013 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17487846 | 0.89 | LMNA (0.41) | PLK4NTRK1PAK4EGFRPIK3C3 | |
| SCHEMBL17488243 | 0.89 | PLK4 (0.42) | PLK4NTRK1PAK4EGFRPIK3C3 | |
| SCHEMBL17488325 | 0.84 | DHODH (0.42) | PLK4NTRK1PAK4EGFRPIK3C3 | |
| SCHEMBL17487841 | 0.84 | DHODH (0.43) | PLK4NTRK1EGFRPIK3C3JAK2 | |
| SCHEMBL17488331 | 0.83 | LMNA (0.39) | PIK3C3 | |
| SCHEMBL17487851 | 0.83 | NPC1 (0.39) | PIK3C3SRC | |
| SCHEMBL17488026 | 0.83 | NTRK1 (0.47) | PLK4NTRK1PAK4EGFRPIK3C3 | |
| SCHEMBL17488019 | 0.82 | PLK4 (0.42) | PLK4NTRK1PAK4 | |
| SCHEMBL18965890 | 0.81 | NTRK1 (0.43) | PLK4NTRK1PAK4JAK2JAK3 | |
| SCHEMBL17488046 | 0.81 | LMNA (0.40) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | PLK4 3683/4885NTRK1 1236/4885PAK4 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.